1982
DOI: 10.1016/s0022-5223(19)37318-0
|View full text |Cite
|
Sign up to set email alerts
|

Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
57
0
3

Year Published

1989
1989
2017
2017

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 370 publications
(60 citation statements)
references
References 9 publications
0
57
0
3
Order By: Relevance
“…This study concluded that there was no justification for doing anything different for younger patients with lung cancer, except that aggressive local resection in the absence of lymph node metastases was indicated. Moreover, evolving surgical opinion in adults suggests that patients with both squamous and adenocarcinoma of the lung and ipsilateral mediastinal metastases detected at thoracotomy may benefit from excision of the tumor and all accessible mediastinal lymph nodes when treated with postoperative irradiation [ 8,9]. Encouraging results in adults suggests that this approach might also be applicable and benefit selected pediatric patients with lung cancer.…”
Section: Case Reportmentioning
confidence: 99%
“…This study concluded that there was no justification for doing anything different for younger patients with lung cancer, except that aggressive local resection in the absence of lymph node metastases was indicated. Moreover, evolving surgical opinion in adults suggests that patients with both squamous and adenocarcinoma of the lung and ipsilateral mediastinal metastases detected at thoracotomy may benefit from excision of the tumor and all accessible mediastinal lymph nodes when treated with postoperative irradiation [ 8,9]. Encouraging results in adults suggests that this approach might also be applicable and benefit selected pediatric patients with lung cancer.…”
Section: Case Reportmentioning
confidence: 99%
“…1 Historical series from experienced centers document dismal survival (7-16% at five years) for patients with clinically obvious N2 NSCLC treated with primary surgery. [2][3][4][5] The five-year survival ranges from 5% to 8% in patients with bulky N2 disease to nearly 35% in patients with single station, microscopic N2 disease. 6 Neoadjuvant (preoperative) therapy for operable NSCLC has been the subject of a large number of studies, but in spite of the progress evidenced by well designed and well conducted phase III randomized trials and meta-analyses, many issues remain unsolved, especially in locally advanced IIIA stage.…”
Section: Introductionmentioning
confidence: 99%
“…Five-year survival following surgical resection without neoadjuvant or adjuvant therapy ranges from 5% for patients with clinically obvious N2 disease to 29% for those with occult N2 disease found within the pathologic specimen [1][2][3][4][5]. Numerous phase II and phase III trials of neoadjuvant chemotherapy or chemoradiation therapy suggest improved long-term patient survival with induction therapy followed by surgical resection [6][7][8][9][10][11][12][13][14].…”
Section: Introductionmentioning
confidence: 99%